Jasper Therapeutics Key Executives
This section highlights Jasper Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Jasper Therapeutics
(Showing 0 of )
Jasper Therapeutics Earnings
This section highlights Jasper Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
$4.39
Stock Price
$65.95M
Market Cap
64
Employees
Redwood City, CA
Location
Financial Statements
Access annual & quarterly financial statements for Jasper Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $1.11M | $1.31M | $566.00K | $21.00K |
| Gross Profit | $- | $-1.11M | $-1.31M | $-566.00K | $-21.00K |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $55.82M | $51.78M | $34.63M | $25.42M | $15.88M |
| General and Administrative Expenses | $20.42M | $17.08M | $16.57M | $11.41M | $4.80M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $20.42M | $17.08M | $16.57M | $11.41M | $4.80M |
| Other Expenses | $- | $- | $586.00K | $-80.00K | $-111.00K |
| Operating Expenses | $76.24M | $68.86M | $51.20M | $36.83M | $20.68M |
| Cost and Expenses | $- | $68.86M | $51.20M | $36.83M | $20.68M |
| Interest Income | $5.06M | $5.20M | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $1.11M | $1.31M | $566.00K | $21.00K |
| EBITDA | $-76.24M | $-64.98M | $-38.21M | $-31.17M | $-31.95M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-76.24M | $-68.86M | $-51.20M | $-36.83M | $-20.68M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $- | $2.77M | $13.51M | $6.20M | $-10.99M |
| Income Before Tax | $- | $-66.09M | $-37.69M | $-30.64M | $-31.67M |
| Income Before Tax Ratio | 0.00% | - | - | - | - |
| Income Tax Expense | $- | $-1.63M | $-13.51M | $-6.65M | $-38.45K |
| Net Income | $- | $-64.47M | $-24.17M | $-23.98M | $-31.67M |
| Net Income Ratio | 0.00% | - | - | - | - |
| EPS | $-4.89 | $-6.18 | $-6.63 | $-21.05 | $-114.30 |
| EPS Diluted | $-4.89 | $-6.18 | $-6.63 | $-21.05 | $-114.30 |
| Weighted Average Shares Outstanding | 14.58M | 10.44M | 3.65M | 1.14M | 277.07K |
| Weighted Average Shares Outstanding Diluted | 14.58M | 10.44M | 3.65M | 1.14M | 277.07K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.17M | $- | $- | $- | $2.05M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $587.00K | $- | $299.00K | $288.00K | $283.00K | $276.00K | $377.00K | $373.00K | $367.00K | $358.00K | $313.00K | $272.00K | $230.00K | $336.00K | $- | $- | $- | $- | $- | $- |
| Gross Profit | $587.00K | $- | $-299.00K | $-288.00K | $1.77M | $-276.00K | $-377.00K | $-373.00K | $-367.00K | $-358.00K | $-313.00K | $-272.00K | $-230.00K | $-336.00K | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 50.00% | 0.00% | - | - | 86.21% | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $19.77M | $14.46M | $11.30M | $10.30M | $13.84M | $14.85M | $13.30M | $9.80M | $9.28M | $9.02M | $8.13M | $8.19M | $8.66M | $7.19M | $5.16M | $4.42M | $4.65M | $4.52M | $4.78M | $1.94M |
| General and Administrative Expenses | $5.51M | $5.43M | $4.70M | $4.77M | $3.89M | $4.51M | $4.53M | $4.14M | $4.46M | $3.69M | $3.83M | $4.59M | $3.42M | $2.89M | $3.26M | $1.83M | $1.31M | $1.49M | $1.24M | $765.00K |
| Selling and Marketing Expenses | $288.00K | $- | $- | $-288.00K | $-283.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.80M | $5.43M | $4.70M | $4.49M | $3.61M | $4.51M | $4.53M | $4.14M | $4.46M | $3.69M | $3.83M | $4.59M | $3.42M | $2.89M | $3.26M | $1.83M | $1.31M | $1.49M | $1.24M | $765.00K |
| Other Expenses | $62.00K | $- | $-40.00K | $-22.00K | $-118.00K | $51.00K | $-109.00K | $-70.00K | $301.00K | $- | $89.00K | $-72.00K | $- | $- | $4.00K | $1.00K | $- | $- | $- | $- |
| Operating Expenses | $25.57M | $19.89M | $15.99M | $14.78M | $17.44M | $19.36M | $17.83M | $13.95M | $13.75M | $12.71M | $11.96M | $12.78M | $12.08M | $10.08M | $8.42M | $6.25M | $5.96M | $6.01M | $9.39M | $1.48M |
| Cost and Expenses | $26.16M | $19.89M | $15.99M | $15.07M | $17.73M | $19.36M | $17.83M | $13.95M | $13.75M | $12.71M | $11.96M | $12.78M | $12.08M | $10.08M | $8.42M | $6.25M | $5.96M | $6.01M | $9.39M | $1.48M |
| Interest Income | $938.00K | $1.28M | $1.45M | $1.39M | $1.23M | $1.43M | $1.44M | $1.10M | $- | $268.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $49.00K |
| Interest Expense | $5.06M | $- | $- | $- | $- | $- | $- | $313.00K | $- | $268.00K | $- | $- | $- | $9.00K | $- | $3.50M | $4.03M | $111.00K | $- | $- |
| Depreciation and Amortization | $-1.13M | $541.00K | $299.00K | $288.00K | $283.00K | $276.00K | $377.00K | $373.00K | $367.00K | $358.00K | $313.00K | $272.00K | $230.00K | $336.00K | $29.00K | $22.00K | $5.96M | $6.01M | $6.01M | $2.71M |
| EBITDA | $45.87M | $-19.35M | $-15.69M | $-14.78M | $-17.44M | $-19.09M | $-17.55M | $-13.67M | $-13.47M | $-12.44M | $-11.74M | $-12.56M | $-11.89M | $-3.07M | $-8.39M | $-6.23M | $-88.27K | $-6.01M | $- | $2.57M |
| EBITDA Ratio | 3907.52% | - | - | - | -850.00% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-25.29M | $-19.89M | $-15.99M | $-15.07M | $-17.73M | $-19.36M | $-17.83M | $-13.95M | $-13.75M | $-12.71M | $-11.96M | $-12.78M | $-12.08M | $-10.08M | $-8.42M | $-6.25M | $-5.96M | $-6.01M | $-6.01M | $-2.71M |
| Operating Income Ratio | -2153.75% | - | - | - | -863.79% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $72.23M | $1.25M | $1.41M | $1.34M | $1.14M | $1.82M | $1.75M | $-313.00K | $536.00K | $845.00K | $1.56M | $10.57M | $3.02M | $6.67M | $4.00K | $-3.50M | $-4.03M | $-4.82M | $-3.41M | $2.80M |
| Income Before Tax | $46.95M | $-18.64M | $-14.58M | $-13.73M | $-16.58M | $-17.54M | $-16.08M | $-14.26M | $-13.21M | $-11.86M | $-10.40M | $-2.21M | $-9.06M | $-3.41M | $-8.41M | $-9.75M | $-9.99M | $-10.82M | $-9.42M | $-1.43M |
| Income Before Tax Ratio | 3998.98% | - | - | - | -808.04% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $54.28K | $- | $-299.00K | $244.72K | $1.91M | $-1.71M | $-1.86M | $1.65M | $-536.00K | $-1.11M | $-1.56M | $-10.57M | $-9.30M | $-132.00K | $-4.00K | $7.00M | $4.03M | $4.71M | $1.20K | $1.27M |
| Net Income | $46.95M | $-18.64M | $-14.58M | $-13.73M | $-16.58M | $-17.54M | $-16.08M | $-15.91M | $-12.68M | $-10.75M | $-8.85M | $8.36M | $-9.06M | $-3.41M | $-8.41M | $-9.75M | $-9.99M | $-10.82M | $-9.42M | $-1.43M |
| Net Income Ratio | 3998.98% | - | - | - | -808.04% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $3.22 | $-1.24 | $-0.97 | $-1.03 | $-1.50 | $-1.60 | $-1.47 | $-1.80 | $-3.46 | $-0.29 | $-0.24 | $0.23 | $-1.82 | $-0.69 | $-0.22 | $-0.26 | $-0.26 | $-0.29 | $-16.08 | $0.00 |
| EPS Diluted | $3.22 | $-1.24 | $-0.97 | $-1.03 | $-1.50 | $-1.60 | $-1.47 | $-1.80 | $-3.46 | $-0.29 | $-0.24 | $0.23 | $-1.82 | $-0.69 | $-0.22 | $-0.26 | $-0.26 | $-0.29 | $-16.06 | $0.00 |
| Weighted Average Shares Outstanding | 14.58M | 15.00M | 14.99M | 13.33M | 11.04M | 10.97M | 10.92M | 8.82M | 3.67M | 36.57M | 36.40M | 36.31M | 4.97M | 4.97M | 37.82M | 37.82M | 37.82M | 37.82M | 586.00K | - |
| Weighted Average Shares Outstanding Diluted | 14.58M | 15.00M | 14.99M | 13.33M | 11.04M | 10.97M | 10.92M | 8.82M | 3.67M | 36.57M | 36.40M | 36.31M | 4.97M | 4.97M | 37.82M | 37.82M | 37.82M | 37.82M | 586.77K | - |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $71.64M | $86.89M | $38.25M | $84.70M | $19.84M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $71.64M | $86.89M | $38.25M | $84.70M | $19.84M |
| Net Receivables | $- | $250.00K | $- | $- | $600.00K |
| Inventory | $- | $- | $- | $-548.00K | $95.47K |
| Other Current Assets | $4.17M | $1.80M | $3.48M | $3.13M | $43.00K |
| Total Current Assets | $75.81M | $88.94M | $41.73M | $87.83M | $20.68M |
| Property Plant Equipment Net | $2.85M | $4.19M | $5.45M | $4.83M | $2.03M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $-980.00K | $-668.00K | $-744.00K |
| Long Term Investments | $- | $- | $417.00K | $345.00K | $345.00K |
| Tax Assets | $- | $- | $563.00K | $323.00K | $399.00K |
| Other Non-Current Assets | $1.24M | $1.76M | $1.18M | $990.00K | $643.00K |
| Total Non-Current Assets | $4.09M | $5.95M | $6.63M | $5.82M | $2.67M |
| Other Assets | $- | $- | $0 | $- | $- |
| Total Assets | $79.90M | $94.89M | $48.36M | $93.65M | $23.36M |
| Account Payables | $4.03M | $4.15M | $1.77M | $3.92M | $1.42M |
| Short Term Debt | $1.09M | $972.00K | $1.73M | $1.01M | $- |
| Tax Payables | $- | $- | $- | $- | $4.55K |
| Deferred Revenue | $- | $- | $- | $2.81M | $- |
| Other Current Liabilities | $10.12M | $7.25M | $3.57M | $3.09M | $2.59M |
| Total Current Liabilities | $15.24M | $12.37M | $7.07M | $8.02M | $4.01M |
| Long Term Debt | $724.00K | $1.81M | $2.79M | $2.38M | $1.62M |
| Deferred Revenue Non-Current | $- | $- | $-563.00K | $-323.00K | $-399.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $563.00K | $323.00K | $399.00K |
| Other Non-Current Liabilities | $2.26M | $2.26M | $2.52M | $13.74M | $52.85M |
| Total Non-Current Liabilities | $2.99M | $4.08M | $5.31M | $16.12M | $54.48M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $18.23M | $16.45M | $12.37M | $24.14M | $58.49M |
| Preferred Stock | $- | $- | $48.36M | $93.65M | $43.84M |
| Common Stock | $2.00K | $1.00K | $4.00K | $4.00K | $1.00K |
| Retained Earnings | $-240.87M | $-169.60M | $-105.14M | $-67.45M | $-36.81M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $0 | $-93.65M | $-43.84M |
| Other Total Stockholders Equity | $302.54M | $248.04M | $141.12M | $136.96M | $-42.16M |
| Total Stockholders Equity | $61.67M | $78.44M | $35.99M | $69.52M | $-35.13M |
| Total Equity | $61.67M | $78.44M | $35.99M | $69.52M | $-35.13M |
| Total Liabilities and Stockholders Equity | $79.90M | $94.89M | $48.36M | $93.65M | $23.36M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $79.90M | $94.89M | $48.36M | $93.65M | $23.36M |
| Total Investments | $- | $417.00K | $417.00K | $345.00K | $345.00K |
| Total Debt | $1.81M | $2.79M | $3.65M | $2.88M | $1.62M |
| Net Debt | $-69.82M | $-84.10M | $-34.60M | $-81.82M | $-18.21M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $71.64M | $92.50M | $106.82M | $118.47M | $86.89M | $103.87M | $115.81M | $129.40M | $38.25M | $50.95M | $60.81M | $70.40M | $84.70M | $100.91M | $309.73K | $590.61K | $19.84M | $757.52K | $914.25K | $-27.16M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $54.33M |
| Cash and Short Term Investments | $71.64M | $92.50M | $106.82M | $118.47M | $86.89M | $103.87M | $115.81M | $129.40M | $38.25M | $50.95M | $60.81M | $70.40M | $84.70M | $100.91M | $309.73K | $590.61K | $19.84M | $757.52K | $914.25K | $27.16M |
| Net Receivables | $- | $250.00K | $250.00K | $250.00K | $250.00K | $268.00K | $330.00K | $- | $- | $384.00K | $443.00K | $563.00K | $- | $298.00K | $- | $- | $600.00K | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $672.00K | $1.77M | $1.87M | $- | $-384.00K | $2.00M | $2.81M | $-698.00K | $1.19M | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $4.17M | $2.05M | $1.61M | $1.58M | $1.80M | $1.08M | $2.42M | $3.11M | $3.48M | $1.08M | $2.03M | $2.84M | $3.13M | $1.20M | $113.20K | $166.19K | $247.00K | $205.99K | $267.08K | $- |
| Total Current Assets | $75.81M | $94.81M | $108.68M | $120.31M | $88.94M | $105.22M | $118.57M | $132.51M | $41.73M | $52.41M | $63.29M | $73.80M | $87.83M | $102.41M | $422.93K | $756.80K | $20.68M | $963.51K | $1.18M | $27.16M |
| Property Plant Equipment Net | $2.85M | $3.18M | $3.67M | $3.81M | $4.19M | $4.36M | $4.74M | $5.11M | $5.45M | $5.74M | $6.09M | $5.72M | $4.83M | $4.46M | $4.05M | $3.65M | $2.03M | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $-1 | $- | $- | $- | $-980.00K | $- | $- | $- | $-668.00K | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $345.00K | $345.00K | $100.13M | $100.20M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $488.00K | $- | $- | $- | $563.00K | $- | $- | $- | $323.00K | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.24M | $1.43M | $1.16M | $1.42M | $1.34M | $411.00K | $445.00K | $725.00K | $1.18M | $543.00K | $577.00K | $611.00K | $990.00K | $- | $-4.05M | $-3.65M | $643.00K | $100.35M | $100.42M | $-27.16M |
| Total Non-Current Assets | $4.09M | $4.61M | $5.25M | $5.65M | $6.44M | $5.19M | $5.60M | $6.25M | $6.63M | $6.70M | $7.08M | $6.75M | $5.82M | $4.81M | $100.13M | $100.20M | $2.67M | $100.35M | $100.42M | $-27.16M |
| Other Assets | $- | $- | $1 | $1 | $1 | $- | $-0 | $- | $0 | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $101.69M |
| Total Assets | $79.90M | $99.41M | $113.93M | $125.96M | $95.38M | $110.41M | $124.17M | $138.76M | $48.36M | $59.11M | $70.37M | $80.55M | $93.65M | $107.21M | $100.55M | $100.96M | $23.36M | $101.32M | $101.60M | $101.69M |
| Account Payables | $4.03M | $3.09M | $2.96M | $2.39M | $4.15M | $3.26M | $1.58M | $3.85M | $1.77M | $3.12M | $3.00M | $1.47M | $3.92M | $2.25M | $4.61M | $1.35M | $1.42M | $- | $- | $- |
| Short Term Debt | $1.09M | $1.06M | $1.03M | $1.00M | $1.94M | $1.89M | $1.83M | $1.78M | $865.00K | $1.68M | $1.57M | $1.04M | $505.00K | $980.00K | $424.00K | $181.00K | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $105.00K | $- | $- | $9.62K | $4.55K | $4.55K | $7.91K | $72.85K | $16.23K |
| Deferred Revenue | $- | $- | $1 | $- | $- | $7.29M | $6.08M | $- | $- | $- | $- | $- | $2.81M | $5.55M | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $10.12M | $8.31M | $6.08M | $5.53M | $6.28M | $6.76M | $5.56M | $2.26M | $4.43M | $2.62M | $2.06M | $3.36M | $3.60M | $5.93M | $-4.72M | $-1.35M | $2.59M | $172.44K | $185.42K | $95.14K |
| Total Current Liabilities | $15.24M | $12.46M | $10.07M | $8.92M | $12.37M | $11.91M | $8.97M | $7.89M | $7.07M | $7.42M | $6.62M | $5.97M | $8.02M | $9.16M | $328.93K | $180.77K | $4.01M | $180.35K | $258.27K | $111.36K |
| Long Term Debt | $724.00K | $1.01M | $1.29M | $1.55M | $1.81M | $2.07M | $2.32M | $2.55M | $2.79M | $3.01M | $3.23M | $3.38M | $2.38M | $2.51M | $2.64M | $2.68M | $1.62M | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-2.26M | $- | $- | $- | $-563.00K | $- | $- | $- | $-323.00K | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $488.00K | $- | $- | $- | $563.00K | $- | $- | $- | $323.00K | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $2.26M | $2.26M | $2.26M | $2.26M | $2.26M | $2.30M | $2.68M | $3.11M | $2.52M | $1.11M | $1.73M | $3.09M | $13.74M | $16.94M | $11.29M | $8.24M | $52.85M | $3.50M | $3.50M | $3.50M |
| Total Non-Current Liabilities | $2.99M | $3.27M | $1.29M | $1.55M | $2.30M | $4.37M | $4.99M | $5.67M | $5.31M | $4.12M | $4.96M | $6.47M | $16.12M | $19.45M | $13.93M | $10.92M | $54.48M | $3.50M | $3.50M | $3.50M |
| Other Liabilities | $- | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $18.23M | $15.73M | $11.36M | $10.47M | $14.68M | $16.27M | $13.96M | $13.56M | $12.37M | $11.54M | $11.59M | $12.44M | $24.14M | $28.61M | $14.26M | $11.10M | $58.49M | $3.68M | $3.76M | $3.61M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $107.21M | $66.25M | $66.25M | $43.84M | $- | $- | $25.84M |
| Common Stock | $2.00K | $2.00K | $2.00K | $2.00K | $1.00K | $11.00K | $11.00K | $11.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $81.29M | $84.86M | $1.00K | $92.64M | $92.84M | $93.08M |
| Retained Earnings | $-240.87M | $-216.55M | $-197.91M | $-183.33M | $-169.60M | $-153.02M | $-135.47M | $-119.39M | $-105.14M | $-91.92M | $-80.06M | $-69.66M | $-67.45M | $-58.39M | $-5.15M | $-1.58M | $-36.81M | $-442.35K | $-241.16K | $2.04K |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $0 | $- | $- | $-0 | $- | $0 | $- | $0 | $-0 | $- | $-107.21M | $0 | $-151.11M | $-43.84M | $- | $- | $-4.73M |
| Other Total Stockholders Equity | $302.54M | $300.23M | $298.22M | $296.56M | $248.04M | $247.14M | $245.67M | $244.58M | $141.12M | $139.49M | $138.84M | $137.76M | $136.96M | $244.20M | $-56.10M | $6.58M | $41.81M | $-87.20M | $-87.60M | $- |
| Total Stockholders Equity | $61.67M | $83.68M | $100.31M | $113.23M | $78.44M | $94.13M | $110.20M | $125.20M | $35.99M | $47.56M | $58.78M | $68.11M | $69.52M | $78.60M | $86.29M | $89.86M | $-35.13M | $5.00M | $5.00M | $21.10M |
| Total Equity | $61.67M | $83.68M | $100.31M | $113.23M | $78.44M | $94.13M | $110.20M | $125.20M | $35.99M | $47.56M | $58.78M | $68.11M | $69.52M | $78.60M | $86.29M | $89.86M | $-35.13M | $5.00M | $5.00M | $21.10M |
| Total Liabilities and Stockholders Equity | $79.90M | $99.41M | $113.93M | $125.96M | $95.38M | $110.41M | $124.17M | $138.76M | $48.36M | $59.11M | $70.37M | $80.55M | $93.65M | $107.21M | $100.55M | $100.96M | $23.36M | $101.32M | $101.60M | $21.10M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $79.90M | $99.41M | $113.93M | $125.96M | $95.38M | $110.41M | $124.17M | $138.76M | $48.36M | $59.11M | $70.37M | $80.55M | $93.65M | $107.21M | $100.55M | $100.96M | $23.36M | $101.32M | $101.60M | $21.10M |
| Total Investments | $- | $- | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $417.00K | $345.00K | $345.00K | $100.13M | $100.20M | $- | $- | $- | $54.33M |
| Total Debt | $1.81M | $2.07M | $2.32M | $2.55M | $2.79M | $3.01M | $3.23M | $3.44M | $3.65M | $3.85M | $4.02M | $3.90M | $2.88M | $3.00M | $2.64M | $2.68M | $1.62M | $- | $- | $- |
| Net Debt | $-69.82M | $-90.43M | $-104.50M | $-115.92M | $-84.10M | $-100.85M | $-112.58M | $-125.95M | $-34.60M | $-47.10M | $-56.80M | $-66.50M | $-81.82M | $-97.90M | $2.33M | $2.09M | $-18.21M | $-757.52K | $-914.25K | $27.16M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-71.27M | $-64.47M | $-37.69M | $-30.64M | $-31.67M |
| Depreciation and Amortization | $1.37M | $1.11M | $975.00K | $377.00K | $21.00K |
| Deferred Income Tax | $- | $- | $- | $3.00M | $-21.00K |
| Stock Based Compensation | $6.62M | $5.21M | $4.09M | $1.05M | $1.21M |
| Change in Working Capital | $173.00K | $5.10M | $-649.00K | $1.62M | $1.30M |
| Accounts Receivables | $- | $663.00K | $-663.00K | $600.00K | $- |
| Inventory | $- | $- | $663.00K | $-600.00K | $- |
| Accounts Payables | $-122.00K | $2.38M | $-2.15M | $2.94M | $358.00K |
| Other Working Capital | $295.00K | $2.06M | $1.50M | $-1.32M | $938.00K |
| Other Non Cash Items | $502.00K | $976.00K | $-12.59M | $-9.09M | $10.90M |
| Net Cash Provided by Operating Activities | $-62.60M | $-52.07M | $-45.86M | $-33.68M | $-18.27M |
| Investments in Property Plant and Equipment | $-552.00K | $-267.00K | $-576.00K | $-2.43M | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $20.00K | $- | $- | $- | $198.34K |
| Net Cash Used for Investing Activities | $-532.00K | $-267.00K | $-576.00K | $-2.43M | $198.34K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $47.20M | $101.93M | $55.00K | $10.75M | $11.29M |
| Common Stock Repurchased | $- | $- | $28.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $689.00K | $-56.00K | $55.00K | $100.97M | $11.29M |
| Net Cash Used Provided by Financing Activities | $47.88M | $100.97M | $55.00K | $100.97M | $11.29M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-198.34K |
| Net Change in Cash | $-15.25M | $48.64M | $-46.38M | $64.86M | $-6.98M |
| Cash at End of Period | $72.05M | $87.30M | $38.67M | $85.05M | $20.18M |
| Cash at Beginning of Period | $87.30M | $38.67M | $85.05M | $20.18M | $27.16M |
| Operating Cash Flow | $-62.60M | $-52.07M | $-45.86M | $-33.68M | $-18.27M |
| Capital Expenditure | $-552.00K | $-267.00K | $-576.00K | $-2.43M | $- |
| Free Cash Flow | $-63.15M | $-52.33M | $-46.43M | $-36.11M | $-18.27M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-24.32M | $-18.64M | $-14.58M | $-13.73M | $-16.58M | $-17.54M | $-16.08M | $-14.26M | $-13.21M | $-11.86M | $-10.40M | $-2.21M | $-9.06M | $-3.41M | $-8.41M | $-9.75M | $-9.99M | $-10.82K | $-9.42K | $-1.43K |
| Depreciation and Amortization | $245.00K | $541.00K | $299.00K | $288.00K | $283.00K | $276.00K | $275.00K | $274.00K | $273.00K | $268.00K | $218.00K | $216.00K | $194.00K | $132.00K | $29.00K | $22.00K | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $-831.00K | $- | $- | $- | $- | $- | $- | $- | $-50.00K | $-450.00K | $- | $3.50M | $- | $- | $- | $- |
| Stock Based Compensation | $1.97M | $2.00M | $1.48M | $1.17M | $1.16M | $1.40M | $1.39M | $1.27M | $1.60M | $644.00K | $1.06M | $778.00K | $231.00K | $195.00K | $295.00K | $327.00K | $437.00K | $316 | $456 | $1 |
| Change in Working Capital | $880.00K | $1.72M | $1.00M | $-3.60M | $-1.42M | $4.12M | $1.46M | $946.00K | $-1.17M | $1.79M | $1.14M | $-2.41M | $-2.89M | $2.68M | $2.21M | $-387.00K | $125.00K | $-161 | $839 | $-1.11K |
| Accounts Receivables | $- | $- | $- | $- | $-663.00K | $- | $- | $663.00K | $-663.00K | $- | $- | $- | $- | $- | $- | $600 | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-283.00K | $- | $- | $283.00K | $663.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $957.00K | $222.00K | $457.00K | $-1.76M | $893.00K | $1.68M | $-2.27M | $2.08M | $-1.35M | $175.00K | $1.48M | $-2.45M | $1.72M | $-410.00K | $1.55M | $83.00K | $-1.24M | $- | $- | $- |
| Other Working Capital | $-77.00K | $1.50M | $545.00K | $-1.84M | $-1.37M | $2.44M | $3.73M | $-2.08M | $178.00K | $1.62M | $-336.00K | $40.00K | $-4.61M | $3.09M | $664.00K | $-470.00K | $1.37M | $-161 | $839 | $-1.11K |
| Other Non Cash Items | $92.00K | $327.00K | $1.74M | $3.64M | $915.00K | $-228.00K | $-318.00K | $1.44M | $-141.00K | $-487.00K | $-1.38M | $-10.59M | $-3.02M | $-6.26M | $88.00K | $96.00K | $4.03M | $2.74K | $4.66K | $1.06K |
| Net Cash Provided by Operating Activities | $-21.13M | $-14.05M | $-11.68M | $-15.74M | $-16.48M | $-11.98M | $-13.27M | $-10.34M | $-12.65M | $-9.64M | $-9.36M | $-14.21M | $-14.58M | $-7.11M | $-5.79M | $-6.20M | $-5.39M | $-7.93K | $-3.47K | $-1.48K |
| Investments in Property Plant and Equipment | $86.00K | $-456.00K | $-157.00K | $-25.00K | $-230.00K | $- | $-11.00K | $-26.00K | $-82.00K | $-222.00K | $-243.00K | $-29.00K | $-711.00K | $-470.00K | $-287.00K | $-960.00K | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-138.24K | $138.24K | $- | $- | $- | $- |
| Other Investing Activities | $238.24K | $-218.24K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-218.24K | $218.24K | $138.24K | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $324.24K | $-674.24K | $-157.00K | $-25.00K | $-230.00K | $- | $-11.00K | $-26.00K | $-82.00K | $-222.00K | $-243.00K | $-29.00K | $-711.00K | $-470.00K | $-287.00K | $-960.00K | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-47.38M | $47.20M | $181.00K | $47.20M | $28.00K | $36.00K | $356.00K | $101.48M | $28.00K | $1.00K | $13.00K | $13.00K | $10.75M | $101.88M | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $45.00K | $- | $- | $-299 | $- | $-661 | $- | $28.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $47.54M | $9.00K | $181.00K | $154.00K | $-271.00K | $36.00K | $-305.00K | $32.00K | $28.00K | $1.00K | $13.00K | $13.00K | $-909.00K | $91.73M | $-600.00K | $10.75M | $10.80M | $- | $- | $484.00K |
| Net Cash Used Provided by Financing Activities | $345.00K | $9.00K | $181.00K | $47.35M | $-271.00K | $36.00K | $-305.00K | $101.51M | $28.00K | $1.00K | $13.00K | $13.00K | $-909.00K | $91.73M | $-600.00K | $10.75M | $10.80M | $- | $- | $484 |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-20.86M | $-14.32M | $-11.66M | $31.59M | $-16.98M | $-11.95M | $-13.59M | $91.15M | $-12.70M | $-9.86M | $-9.59M | $-14.23M | $-16.20M | $84.15M | $-6.68M | $3.60M | $5.41M | $-7.93K | $-3.47K | $-993 |
| Cash at End of Period | $72.05M | $92.92M | $106.82M | $118.47M | $86.89M | $104.28M | $116.23M | $129.82M | $38.67M | $51.37M | $61.23M | $70.82M | $85.05M | $101.25M | $17.10M | $23.78M | $20.18M | $14.77K | $22.70K | $26.17K |
| Cash at Beginning of Period | $92.92M | $107.24M | $118.47M | $86.89M | $103.87M | $116.23M | $129.82M | $38.67M | $51.37M | $61.23M | $70.82M | $85.05M | $101.25M | $17.10M | $23.78M | $20.18M | $14.77M | $22.70K | $26.17K | $27.16K |
| Operating Cash Flow | $-21.13M | $-14.05M | $-11.68M | $-15.74M | $-16.48M | $-11.98M | $-13.27M | $-10.34M | $-12.65M | $-9.64M | $-9.36M | $-14.21M | $-14.58M | $-7.11M | $-5.79M | $-6.20M | $-5.39M | $-7.93K | $-3.47K | $-1.48K |
| Capital Expenditure | $-96.00K | $-274.00K | $-157.00K | $-25.00K | $-230.00K | $- | $-11.00K | $-26.00K | $-82.00K | $-222.00K | $-243.00K | $-29.00K | $-711.00K | $-470.00K | $-287.00K | $-960.00K | $- | $- | $- | $- |
| Free Cash Flow | $-21.23M | $-14.33M | $-11.84M | $-15.76M | $-16.71M | $-11.98M | $-13.28M | $-10.36M | $-12.73M | $-9.87M | $-9.60M | $-14.24M | $-15.29M | $-7.58M | $-6.08M | $-7.16M | $-5.39M | $-7.93K | $-3.47K | $-1.48K |
Jasper Therapeutics Dividends
Explore Jasper Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Jasper Therapeutics News
Read the latest news about Jasper Therapeutics, including recent articles, headlines, and updates.
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA.
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced a late-breaking oral presentation of briquilimab data from the Phase 1b/2a BEACON in CSU study at the 2025 AAD Annual Meeting, being held March 7 - 11, 2025, in Orlando, FL. The presentation will consist of data from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the BEACON study.
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2024 and provided a corporate update.
Jasper Therapeutics to Present at Upcoming March Investor Conferences
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences in March.
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced five poster presentations and an oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The oral presentation and one of the poster presentations will include additional follow-up from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the Phase 1b/2a BEACON trial evaluating briquilimab in CSU.
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Oppenheimer Healthcare Life Sciences Conference, taking place February 11-12, 2025.
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Jasper will host a virtual webinar on Wednesday, January 8, 2025, to present preliminary data from the BEACON study of briquilimab in CSU.
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the first patient has been dosed in Jasper's Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN (Evaluating The Efficacy and Safety of briquilimab In participANts with allergic asthma). The ETESIAN study is evaluating a single administration of subcutaneous briquilimab in patients with asthma.
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma
Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved markets. Despite positive preliminary clinical results, Jasper faces financial risks, needing additional funds by Q3 2025, which may lead to shareholder dilution. Analysts rate JSPR as a strong buy with a $69.5 target, but caution is advised due to the speculative nature and financial instability.
Jasper Therapeutics to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences:
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2024, provided a corporate update and announced the closure of Jasper's legacy clinical study in lower-risk myelodysplastic syndromes (LR-MDS).
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24-28, 2024, in Boston, Massachusetts.
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?
On Monday, Jasper Therapeutics Inc JSPR stock is trading higher after the company reported preliminary data from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD).
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6 th , 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif.
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company's Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study evaluating briquilimab in asthma.
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences in September:
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024.
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24, 2024, in New York City.
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematology Association (EHA) Hybrid Congress, being held June 13 – 16, 2024 in Madrid, Spain.
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress presentations from its BEACON and SPOTLIGHT clinical studies, at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain.
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Jefferies Global Healthcare Conference at 4:00pm EDT on Wednesday, June 5, 2024.
Equities Analysts Offer Predictions for Jasper Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:JSPR)
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) – Equities research analysts at Capital One Financial upped their Q2 2024 earnings per share estimates for shares of Jasper Therapeutics in a research report issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now anticipates that the company will post earnings per share of ($1.19) for the quarter, up from their prior estimate of ($1.24). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.35) per share. Capital One Financial also issued estimates for Jasper Therapeutics’ FY2024 earnings at ($4.64) EPS, FY2025 earnings at ($5.08) EPS, FY2026 earnings at ($5.58) EPS, FY2027 earnings at ($2.74) EPS and FY2028 earnings at $2.23 EPS. A number of other equities research analysts also recently commented on JSPR. Oppenheimer reiterated an “outperform” rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Evercore ISI started coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an “outperform” rating and a $65.00 target price for the company. TD Cowen assumed coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Wednesday, May 15th. Finally, Royal Bank of Canada began coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 target price on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $64.29. Read Our Latest Stock Report on JSPR Jasper Therapeutics Price Performance JSPR stock opened at $23.02 on Monday. The firm has a market cap of $346.68 million, a PE ratio of -4.09 and a beta of 2.25. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The firm has a 50 day simple moving average of $25.12 and a 200 day simple moving average of $15.85. Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last posted its quarterly earnings data on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. Institutional Investors Weigh In On Jasper Therapeutics A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Opaleye Management Inc. acquired a new position in shares of Jasper Therapeutics in the fourth quarter worth $3,144,000. Kingdon Capital Management L.L.C. grew its stake in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after purchasing an additional 500,000 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Jasper Therapeutics in the 4th quarter worth about $197,000. Cowen AND Company LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter worth about $140,000. Finally, StemPoint Capital LP acquired a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Hedge funds and other institutional investors own 79.85% of the company’s stock. Jasper Therapeutics Company Profile (Get Free Report) Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. Read More Five stocks we like better than Jasper Therapeutics What is the Euro STOXX 50 Index? MarketBeat Week in Review – 5/13 – 5/17 Low PE Growth Stocks: Unlocking Investment Opportunities Take-Two Interactive Software Offers 2nd Chance for Investors How to Effectively Use the MarketBeat Ratings Screener Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments.
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b/2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024.
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May:
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for JSPR.